Skip to main content

Table 1 Reproductive performance of p53+/- females treated with cyclophosphamide (CP) and tested on day 16 of pregnancy.

From: Teratogen-induced alterations in microRNA-34, microRNA-125b and microRNA-155 expression: correlation with embryonic p53 genotype and limb phenotype

  Groups of females
Indices Control CP (12.5 mg/kg) CP (20 mg/kg) CP (40 mg/kg)
Number of pregnant females 8 10 14 10
Implantation sites/litter 66/8.3 84/8.4 106/7.6 83/8.3
Percent of resorptions
(arcsine, mean ± SE)
6.1
(16.2 ± 3.4) a
4.8
(15.4 ± 2.5) a
13.2
(23.5 ± 3.6)a
26.5
(32.0 ± 2.0) b
Number of live fetuses     
Total 62 80 92 61
p53+/+ 18 (29%) 14 (17.5%) 16 (17.4%) 18 (29.5%)
p53+/- 27 (43.6%) 46 (57.5%) 48 (52.2%) 36 (59%)
p53-/- 17 (27.4%) 20 (25%) 28 (30.4%) 7 (11.5%)
  1. Superscripts denote results of statistical analysis of values within a row. Values not sharing common superscripts are significantly different (the GT-2 test, p < 0.05).